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Abstract
 
Growth factors can cause cells to proliferate, differentiate, survive, or die. Distinguishing be-
tween these responses is difficult in multicellular, multiparameter systems. Yet this is essential to
understand the impact on cells like hematopoietic stem cells (HSCs), which have strict and still
poorly understood growth factor requirements. Single cell plating in serum-free medium al-
lows direct assessment of growth factor responses. The range of tested factors can be expanded
if the cells are protected from growth factor deprivation–induced apoptosis. BCL-2 is overex-
pressed in HSCs of H2K-
 
BCL
 
-2 transgenic mice, protecting them from many apoptotic stim-
uli. The response of single wild-type and transgenic HSCs to stimulations with individual fac-
tors was tested. Surprisingly, we find that high level BCL-2 expression does not prevent rapid
death under serum-free conditions, even though it does in the presence of serum. We also find
that transgenic, but not wild-type cells, survive and proliferate rapidly in response to steel factor
(Kit ligand). These studies show that two separate signals are necessary to prevent apoptosis in
HSCs, and that Kit ligand by itself provides a strong proliferative stimulus to HSCs. However,
the proliferative response does not result in self-renewal, but in differentiation to all known he-
matopoietic oligolineage progenitors.
Key words: hematopoietic stem cell • transgenic mice • ﬂow cytometry • stem cell factor • 
serum-free medium
 
Introduction
 
Hematopoietic stem cells (HSCs)
 
1
 
 in mice have been de-
scribed using different surface marker combinations (for a
review, see reference 1). Using monoclonal antibodies, all
HSC activity in mouse bone marrow resides within Thy-
1.1
 
low
 
, Sca-1
 
pos
 
, Lin
 
neg/low
 
, and c-Kit
 
pos
 
 cells (2–4). Although
 
representing only 
 
z
 
1/2,000 bone marrow cells, this is still a
heterogeneous population. In the mouse, these cells can be
divided by surface phenotype into cells that have long-term
multilineage reconstitution potential and which can func-
tion for the lifetime of the animal (long-term HSCs [LT-
HSCs]) and those that have only short-term multilineage
reconstitution potential (short-term HSCs [ST-HSCs]),
typically 8–12 wk in mice (5). LT-HSCs, 
 
z
 
0.01–0.02% of
bone marrow, are characterized by the total absence of lin-
eage markers (Lin
 
neg
 
), whereas cells with short-term recon-
stitution potential are characterized by low level staining of
some of these markers (Lin
 
low
 
 [5]). ST-HSCs are derived
from LT-HSCs (6). The limit dilution titration (dose at
which recipient animals are reconstituted by one cell on av-
erage) for both populations is 
 
z
 
10 cells (5). This shows that
these populations are (virtually) homogenous with respect
to reconstitution activity, taking into account that only
 
z
 
10% of injected HSCs home to the bone marrow (7). It
should be noted that HSC surface marker profiles can differ
between strains (8), alleles (9), developmental stages (10),
and activation stages (11, 12). Most of the experiments de-
scribed here compare a transgenic model with wild-type
littermates. Transgenic HSCs cannot be assumed to display
the same surface markers as wild-type mice. However, we
have previously extensively characterized the HSCs in
H2K-
 
BCL
 
-2 transgenic mice and found that they have the
same surface markers as wild-type mice. Both LT-HSCs
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and ST-HSCs can be purified to the same degree, and their
in vivo reconstitution potential is at least as good as that of
their wild-type littermates (13).
HSCs are characterized by their ability to both self-
renew and differentiate, and thus give rise to the various
kinds of mature hematopoietic cells (14). Self-renewal is
readily apparent in vivo. For example, the number of func-
tional HSCs that can be isolated from mice after HSC
transplantation clearly exceeds input numbers (6, 15, 16).
Expansion under these conditions can be manipulated by
coinjection of growth factors such as Kit ligand (Kitl) and
IL-11 (16). However, despite extensive efforts, methods to
expand HSCs in vitro to an appreciable extent have to our
knowledge not yet been reported (17). The characteriza-
tion of multiple growth factors, stroma cell lines, and cul-
ture systems has failed to yield a culture system in which
more than maintenance or possible minor expansions oc-
cur. This severely limits the use of HSCs for retroviral gene
transfer experiments as well as for clinical use, especially
when limited numbers of HSCs are available.
After cell division, HSCs are subject to three different
cell fates: self-renewal, differentiation, and apoptosis (1,
13). To expand HSCs (symmetric self-renewing divisions),
the stimuli offered to the cells must not only stimulate pro-
liferation, but also prevent differentiation and apoptosis.
Blocking of apoptosis is not enough to maintain HSCs.
Overexpression of Bcl-2 prevents apoptosis in hematopoi-
etic cells (18), but does not prevent spontaneous differenti-
ation in a progenitor cell line, even in the absence of
growth factors (19). Overexpression of BCL-2 in HSCs in
vivo in a transgenic mouse model (13, 20) results in pro-
tection from apoptosis, but only in a moderate (twofold)
expansion, even though these HSCs outcompete wild-type
HSCs after reconstitution (13). This model demonstrates
that apoptosis is an important factor in the regulation of
HSCs. However, BCL-2 overexpression is not sufficient
for massive expansion of HSCs. The presence of other sig-
nals, presumably those regulating differentiation, as well as
apoptosis that is not prevented by Bcl-2 overexpression,
may account for this.
To obtain more insight into the functions of growth fac-
tors on HSCs, blocking of apoptosis versus stimulation of
proliferation or differentiation, we have studied HSCs from
H2K-
 
BCL
 
-2 transgenic mice, which overexpress BCL-2
(13, 20). Growth factor stimulations were studied using
single cell platings in vitro, under serum-free conditions.
This makes it possible to determine the response rate of in-
dividual cells, a method which has been used to study the
symmetry of HSC divisions and the surface phenotype of
daughter cells during initial divisions (21, 22). We find that
HSCs that are blocked in apoptosis by BCL-2 overexpres-
sion respond to several individually assayed growth factors
(thrombopoietin [Tpo], IL-3, and Kitl) in a more pro-
nounced way than wild-type HSCs. Most dramatic is the
response to Kitl, which induces rapid proliferation in the
majority of the plated transgenic, but not wild-type, cells.
However, although single factor stimulation of HSCs over-
expressing BCL-2 in vitro can lead to rapid proliferation,
 
there is no evidence for expansion of cells with the HSC
phenotype. Neither Kitl nor 
 
BCL
 
-2 actively maintains the
undifferentiated state of HSCs. The combination of H2K-
 
BCL
 
-2 transgenic HSCs and the culture conditions de-
scribed here form a powerful tool to study HSC growth
factor requirements. They are used here to demonstrate
that HSCs depend on two signals to prevent apoptosis.
 
Materials and Methods
 
Transgenic Mice.
 
H2K-
 
BCL
 
-2 transgenic mice have been de-
scribed (20). Transgenic status was determined by flow cytomet-
ric screening for human BCL-2 protein in peripheral blood cells.
Mice from three independent founder lines (1038, 1043, and
1053) were used to prevent integration site–specific phenotypes
from obscuring the results. The transgenic mice were backcrossed
at least 10 times onto C57Bl/Ka Thy-1.1 mice. All mice were
bred at the animal care facility at the Stanford University School
of Medicine. Mice were maintained on acidified water (pH 2.5).
 
Tissue Culture.
 
One or two LT-HSCs (Thy-1.1
 
low
 
Lin
 
neg
 
Sca-
1
 
pos
 
c-Kit
 
high
 
) or ST-HSCs (Thy-1.1
 
low
 
Lin
 
low
 
Sca-1
 
pos
 
c-Kit
 
high
 
) de-
rived by two successive sorts were deposited per well in 60-well
Terasaki plates (Nunc) using the single cell deposition unit and
Clone-cyt™ software (Becton Dickinson) on a modified FACS
Vantage™. The wells contained 10 
 
m
 
l of serum-free medium
(Xvivo15; BioWhittaker) supplemented with 5 
 
3 
 
10
 
2
 
5 
 
M
 
b
 
-mercaptoethanol and experimentally added growth factors.
The cells in each well were counted under an inverted microscope
at regular intervals. Factors tested include IL-1 (5 ng/ml; GIBCO
BRL), IL-2 (100 U/ml; Collaborative Research), IL-3 (300 ng/
ml; Genzyme), IL-4, IL-6 (10 ng/ml; GIBCO BRL), IL-7 (30
ng/ml; Genzyme), IL-11 (25 ng/ml; Stem Cell Technologies),
Kitl (30 ng/ml; R&D Systems), Flt3 ligand (Flt3-L, 30 ng/ml;
R&D Systems), Tpo (100 ng/ml; Genzyme), G-CSF (100 ng/ml;
Amgen), GM-CSF (10 ng/ml; Genzyme), TNF-
 
a
 
, TGF-
 
b
 
 (100
ng/ml; R&D Systems), macrophage inflammatory protein
(MIP)-1
 
a
 
 (100 ng/ml; Genzyme), bone morphogenetic protein
4 (BMP-4) (100 ng/ml; R&D Systems), leukemia inhibitory fac-
tor (LIF, 10
 
4
 
 U/ml; GIBCO BRL), oncostatin M (OSM, 250
ng/ml; R&D Systems), erythropoietin (Epo, 1 U/ml; Ortho),
basic fibroblast growth factor (bFGF, 100 ng/ml; GIBCO BRL),
epidermal growth factor (EGF, 100 ng/ml; R&D Systems), and
vascular endothelial growth factor (VEGF)
 
164
 
 (40 ng/ml; R&D
Systems). For some experiments (growth factor deprivation ex-
periments) serum-containing medium (M5300; Stem Cell Tech-
nologies) was used.
 
Cytospin Staining and Photography.
 
Cells were collected on
slides using a cytospin (Shandon) directly after sorting or after
culture. The slides were air dried and stained with May-Grün-
wald (Fluka) for 3 min followed, after washing, by a 20-min in-
cubation in Giemsa stain (Fluka), diluted 1:20 in water. Photo-
graphs were taken on Ektachrome slide film (100 ASA; Eastman
Kodak Co.) using a Microphot FXA microscope (Nikon). Slides
were digitized using a Coolscan III (Nikon). Representative cells
were selected from digitized photographs using Adobe Photo-
shop
 
®
 
 4.0.1 and labeled using Deneba Canvas
 
® 
 
7.0.1 software run
on Power Macintosh G3 and G4 computers.
 
Flow Cytometry.
 
Sorting of HSCs was modified from previ-
ously published protocols (see, for example, reference 20). In
brief, bone marrow cells are stained with FITC-19XE5 (anti-
Thy1.1), lineage cocktail, Texas red–E13-161-7 (anti–Sca-1),
allophycocyanin (APC)-2B8 (anti–c-Kit), and biotin-3C11 (anti– 
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c-Kit). The cells are enriched for c-Kit
 
1
 
 cells using MACS col-
umns and streptavidin microbeads (Miltenyi Biotec). Enriched
cells are sorted as described. The lineage cocktail consists of the
following antibodies: KT31.1 (anti-CD3), GK1.5 (anti-CD4),
53-7.8 (anti-CD5), 53-6.7 (anti-CD8), 6B2 (anti-B220), Ter119
(anti-TER119), M1/70 (anti–Mac-1), and 8C5 (anti–Gr-1).
They are used either directly conjugated to PE, or are visualized
by secondary antibodies (anti–rat PE or anti–rat Cy5PE). Labeled
cells were analyzed and sorted with a dual laser FACS Vantage™
(Becton Dickinson), made available through the FACS
 
®
 
 shared
user group at Stanford University. Flow cytometry data were an-
alyzed using FACS
 
®
 
/Desk (Stanford University) or FlowJo
(Treestar Inc.). Dead cells were excluded from analysis by their
propidium iodide staining characteristics. Two parameter data are
presented as 5% probability plots with outliers.
The rat antibodies 53-7.3 (anti-CD5), 53-6.7 (anti-CD8),
Ter-119 (anti-erythro), GK1.5 (anti-CD4), KT31.1 (anti-CD3),
6B2 (anti-B220), M1/70 (anti–Mac-1), 8C5 (anti–GR-1), E13-
161 (anti–Sca-1), 3C11 (anti–c-Kit), and 2B8 (anti–c-Kit) were
prepared from the respective hybridoma clones, as were their
conjugates. Secondary antibodies were obtained from Caltag.
Avidin–Texas red was obtained from Cappel. Anti–human BCL-2
(clone 124) was purchased from Dako.
 
CFU–Spleen Assays.
 
The lethal preconditioning regimen for
CFU–spleen (CFU-S) assays was 9.5 Gy total body irradiation,
given in two doses with a 3-h interval using a 200-kV x-ray ma-
chine. Host mice, 8–12-wk-old C57Bl/Ka mice, were given an-
tibiotic water (1.1 g/liter neomycin sulfate and 10
 
6
 
 U/liter poly-
myxin B sulfate) after irradiation. Spleens were harvested at day
12 and colonies were counted after fixation in Tellesniczky fixa-
tive (75% ethanol, 3.75% acetic acid, and 7.5% formalin).
 
Results
 
Experimental Model to Test Growth Factor Responses of Sin-
gle HSCs.
 
We have previously extensively characterized
the HSCs present in H2K-
 
BCL
 
-2 transgenic mice. We
have shown that these HSCs express the same surface
markers as wild-type HSCs. Reconstitution experiments in
vivo have demonstrated that HSCs isolated from transgenic
mice behave similar to wild-type HSCs in that they recon-
stitute donors as efficiently as cells from wild-type mice,
and short-term and long-term HSCs still behave as ST-
HSCs and LT-HSCs. Transgenic HSCs express the trans-
gene and are protected against apoptosis. H2K-
 
BCL
 
-2
transgenic mice have more (approximately twofold) HSCs
than wild-type mice, and these HSCs cycle slower; that is,
fewer transgenic HSCs than wild-type cells have 
 
.
 
2n
DNA (approximately twofold reduction) (13, 20). Fig. 1 A
shows in detail the extent to which H2K-
 
BCL
 
-2 transgenic
LT-HSCs and ST-HSCs are protected from growth factor
deprivation in the presence of serum.
The growth factor responses of single plated HSCs were
tested in serum-free medium. LT-HSCs and ST-HSCs
were sorted as described previously (13). The sorted HSCs
are resorted in clone-sort mode, and single cells are depos-
ited into the wells of 60-well Terasaki plates containing 10
 
m
 
l Xvivo15 serum-free medium, with or without added
growth factors. Fig. 1 B illustrates the response range in this
assay. Depending on the factor(s) added, the plated HSCs
will either die rapidly (no factors), a subset will remain
present without extensive proliferation (Kitl added), or
most or all cells will proliferate rapidly and extensively
(cocktail of factors added). The difference between trans-
genic and wild-type HSCs is minimal; both have a similar
response range. The delay in cell cycle entry that BCL-2
overexpression can cause (23, 24) and that results in slower
cycling, as detected by 5-bromo-2
 
9
 
-deoxyuridine (BrdU)
Figure 1. Assay parameters for single cell plating of HSCs in Terasaki
wells. (A) Factor deprivation–induced apoptosis in the presence of serum.
Linneg (left) and Linlow (right) HSCs were deposited as single cells in
Terasaki wells with serum-containing M5300 medium without factors.
At the indicated time points, a mixture of recombinant murine (rm)Kitl,
rmFlt3-L, rmIL-6, and rmTpo was added and the wells with proliferating
cells were counted 5–7 d later. 60–120 cells were plated per genotype per
time point. Filled symbols and thick lines show transgenic cells, and open
symbols and thin lines show wild-type cells. Circles and diamonds indi-
cate separate sets of experiments. 100% is the plating efficiency of cells to
which growth factors are added at time 0. (B) Single LT-HSCs are clone
sorted into wells of Terasaki plates containing serum-free medium
(Xvivo15) without growth factors (thin lines and small open symbols),
with 30 ng/ml rmKitl (medium lines and large open symbols), or a mix-
ture of IL-1, IL-3, IL-6, Kitl, and Flt3-L (thick lines and filled symbols).
Data from three separate experiments are shown, with 20 cells plated per
condition per experiment. Cell numbers at each time point are plotted as
total cell numbers present in all wells divided by the number of cells
plated initially in the experiment. (C) Comparison of survival times of
LT-HSCs plated in the presence of serum (dashed lines; data from A) or
in the absence of serum (solid lines). The assays in serum-free medium
were done as described in B but show data from three additional experi-
ments with 20 plated cells each. 
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labeling of H2K-
 
BCL
 
-2 HSCs in vivo (13), is not detect-
able under these conditions. Cell death in serum-free me-
dium without added factors happens much more rapidly for
H2K-
 
BCL
 
-2 transgenic HSCs than in the presence of se-
rum (Fig. 1 C). This shows that BCL-2 overexpression by
itself is not enough to ensure survival under serum-free
culture conditions; other stimuli are necessary.
 
The Response of HSCs to Single Factor Stimulation.
 
This
experimental model was used to study the effect of single
factor stimulations to identify factor(s) that can collaborate
with BCL-2. As the most important function of several cy-
tokines seems to be preventing apoptosis (for reviews, see
references 1 and 25), transgenic HSCs might be able to re-
spond to cytokines whose function does not include pre-
vention of apoptosis. A large number of cytokines were
tested in Xvivo15 medium. As expected, most, including
IL-1, IL-2, IL-4, IL-6, IL-7, IL-11, Flt3-L, G-CSF, GM-
CSF, TNF-
 
a
 
, TGF-
 
b
 
, MIP-1
 
a
 
, BMP-4, LIF, OSM, Epo,
bFGF, EGF, and VEGF, did not elicit a response from ei-
ther genotype. Fig. 2 A (top) shows GM-CSF as an exam-
ple. Tpo, Kitl, and IL-3 did elicit a response (Fig. 2 A).
Both wild-type and transgenic HSCs respond to IL-3 with
vigorous proliferation (Fig. 2 A, bottom). A very limited
response, stronger for transgenic than for wild-type cells, to
Tpo alone is seen. Cell numbers never exceed input num-
bers, averaged over the plated cells per experiment.
The most dramatic difference between wild-type and
transgenic HSCs was seen in Kitl stimulations. Wild-type
HSCs plated in serum-free medium supplemented with
Kitl responded by maintaining cell numbers at 
 
z
 
20% of in-
put numbers for at least 1 wk with limited proliferation in a
subset of wells (see below). Eventually, in a few wells this
can be followed by more pronounced proliferation. In
contrast, wells with single H2K-
 
BCL
 
-2 transgenic HSCs
display a much more vigorous response. Fig. 2 B illustrates
the response of a single H2K-
 
BCL
 
-2 transgenic LT-HSCs
stimulated with Kitl. LT-HSCs and ST-HSCs respond sim-
ilarly to the factors tested.
 
More H2K-BCL-2 HSCs Respond to Single Factor Stimula-
tion.
 
The increased cell numbers derived from transgenic
HSCs under these conditions can represent increased pro-
liferation of a subset of cells, or an increased number of
cells responding. As HSCs are plated as single cells, it is
possible to distinguish between these options. Fig. 3 A
shows the percentage of plated cells that undergoes cell di-
vision, that is, the percentage of wells in which two or
more cells are present after the plating of one cell. In the
absence of added growth factors, or in the presence of fac-
tors that do not elicit a response, cell division is (virtually)
absent. The lowest positive response of LT-HSCs (Fig. 3
A, top) is to stimulation with Tpo; 
 
,
 
1% of wild-type, and
 
z
 
10% of transgenic cells divide, and the average clone size
is very small. The highest response rate of LT-HSCs is to
Kitl. Although only 
 
z
 
10% of wild-type LT-HSCs divide,
not different from the response to IL-3, 
 
.
 
50% of the
plated transgenic LT-HSCs divide. In addition, the clone
sizes are often large. ST-HSCs (Fig. 3 A, bottom) behave
similar to LT-HSCs. There is both early and delayed Kitl
Figure 2. Single factor stimula-
tions of LT-HSCs and ST-HSCs.
(A) Single HSCs were clone sorted
into wells of Terasaki plates in se-
rum-free medium (Xvivo15) with
a single added factor, as indicated.
Thin lines and open symbols show
data for wild-type cells, and thick
lines and filled symbols show data
for H2K-BCL-2 transgenic HSCs.
Cell numbers at each time point
are plotted as total cell numbers
present in all wells divided by the
number of cells plated initially in
the experiment. Representative
experiments are shown. (B) Cell
growth after plating of a single LT-
HSC in a Terasaki well. Numbers
indicate days in culture. The pic-
tures illustrate growth of one
H2K-BCL-2 transgenic LT-HSC
stimulated with Kitl. 
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induced initiation of proliferation of HSCs. As depicted in
Fig. 3 B, additional H2K-
 
BCL
 
-2 transgenic LT-HSCs are
continuously induced into initiating proliferation, even af-
ter prolonged (at least up to 3 wk) dormancy (in the pres-
ence of Kitl) in culture. In contrast, proliferation induced
by factors such as IL-3 happens within a few days of plat-
ing, independent of the transgenic status. There is no evi-
dence that proliferation of transgenic HSCs is delayed, de-
spite the fact that fewer transgenic HSCs are in cycle when
isolated (13).
 
Kitl Does Not Expand H2K-BCL-2 LT-HSCs.
 
HSCs
that proliferate under the conditions described do not
 
maintain their phenotype, but differentiate primarily into
early myeloid cells. Fig. 4 A shows typical wells in which a
single H2K-
 
BCL
 
-2 transgenic LT-HSC was cultured in
Tpo, IL-3, or Kitl. Tpo-stimulated wells have few cells,
some of which are extremely large. IL-3–stimulated wells
have many medium-sized cells. Kitl-stimulated wells have a
wide range of cell numbers, but the cells are typically
smaller than in IL-3–stimulated wells. This is confirmed by
cytospins (Fig. 4 B). Tpo-stimulated cultures contain ma-
ture-looking megakaryocytes and IL-3–stimulated cultures
contain well-differentiated myeloid cells of various lin-
eages, whereas Kitl-stimulated cells, even after 14 d in cul-
ture, contain mainly undifferentiated blast cells, in addition
to poorly differentiated myeloid cells. The cells are larger
than freshly isolated LT-HSCs, in line with their rapid cy-
cling. There is no clear difference in IL-3– or Tpo-induced
differentiation between transgenic and wild-type cultures.
Flow cytometric analysis (Fig. 5) of LT-HSCs cultured
in serum-free medium plus Kitl confirms their slow differ-
entiation. The top left panel of Fig. 5 depicts the difference
in cell numbers of wild-type (thin lines) and H2K-
 
BCL
 
-2
transgenic (bold lines) LT-HSCs in a typical experiment.
When cultures are tested for maintenance of day 12 CFU-S,
as a measure for maintenance of HSCs and multipotent
progenitors, CFU-S activity drops rapidly in wild-type cul-
tures, as expected (Fig. 5, second panel, top). Transgenic
cultures show an initial increase, but numbers drop rapidly
as the cells increase their proliferation rate. The third and
consecutive panels do not take into account the difference
in cell numbers between wild-type and transgenic cultures
(first panel), which makes the actual difference considerably
larger. Phenotypic HSCs (Thy-1.1
 
low
 
Lin
 
neg/low
 
Sca-1
 
pos
 
c-
Kit
 
pos
 
) decline rapidly in wild-type cultures. In transgenic
cultures the decline is slower but, even taking the differ-
ence in absolute numbers into account, still present. This
confirms the CFU-S data: H2K-
 
BCL
 
-2 transgenic HSCs
do not expand under these conditions. Other progenitors
studied include common lymphoid progenitors (CLPs),
which can give rise to B, T, and NK cells (26), common
myeloid progenitors (CMPs), which can give rise to all
myeloid lineages (27), and the more restricted megakaryo-
cyte/erythrocyte progenitors (MEPs) and granulocyte/
macrophage progenitors (GMPs [27]). Cells with CLP
phenotype appear late and are present in very low num-
bers. However, sorting and replating of these cells on AC6
stroma cells supplemented with IL-7 show that they, like
bone marrow CLPs, will give rise to B cells (B220
 
1
 
CD19
 
1
 
; data not shown). Myeloid progenitors appear ear-
lier and in larger numbers in these cultures, with the bal-
ance gradually shifting towards GMPs. The vast majority of
the cells differentiate into myeloid cells (Gr-1– and/or
Mac-1–positive; Fig. 5, bottom right panel). TER119
 
1
 
erythroid cells and B lymphoid cells (not shown) remain
near background levels. However, this analysis excludes
mature erythrocytes.
There are no clear differences between H2K-
 
BCL
 
-2
transgenic and wild-type cultures with respect to the rela-
tive levels of progenitors and more mature cells or in the
Figure 3. Proliferation in response to single factor stimulation. (A) The
panels show the percentage of proliferating cells (wells with two or more
cells per well after plating a single cell) after incubation in Xvivo15 with
rmTpo, rmIL-3, or rmKitl. Bold lines and filled symbols show H2K-
BCL-2 HSCs, and thin lines and open symbols show wild-type cells. The
figure shows data for 180 plated cells per genotype per condition (Tpo
and IL-3) or 60 plated cells (Kitl). Representative experiments are shown.
(B) Cell numbers in individual wells after plating of wild-type (left) or
H2K-BCL-2 (right) LT-HSCs as single cells into Terasaki plates contain-
ing Xvivo15 and 60 ng/ml rmIL-3, or Xvivo15 and 30 ng/ml rmKitl.
Data are from 60 cells plated per experimental condition. The figure only
shows the traces for wells in which at least one cell division occurred;
traces for wells without proliferation basically coincide with the x-axis. 
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Figure 4. Cell morphology of H2K-BCL-2
LT-HSCs exposed to Tpo, IL-3, or Kitl. (A)
Overview of the wells grown serum free with
the cytokines as indicated. The cultures were
initiated by deposition of a single, double-
sorted, H2K-BCL-2 transgenic LT-HSC. (B)
Morphology of the cells growing in IL-3–,
Tpo-, and Kitl-stimulated serum-free cul-
tures. The cultured cells are compared with
freshly isolated LT-HSCs and ST-HSCs. The
cell cultures were initiated from H2K-BCL-2
transgenic LT-HSCs. For staining and pho-
tography, see Materials and Methods. Repre-
sentative cells are shown.
Figure 5. Differentiation in response to Kitl
stimulation. The top left panel shows total cell
numbers after plating of single LT-HSCs in
Xvivo15 medium plus Kitl. Cell numbers at each
time point are plotted as total cell numbers present
in all wells divided by the number of cells (60 cells)
plated initially in the experiment. The second top
panel depicts CFU-S day 12 activity of LT-HSCs
cultured for various periods of time in Kitl. For
each time point the cells from four wells (1,000
cells plated) were collected and injected into five
lethally irradiated mice to determine the CFU-S
day 12 activity. The third and top right panels show
flow cytometric analysis enumerating, as percentage
of live cells, the populations indicated. The bottom
right panel shows the presence of cells with more
mature surface markers Gr-1/Mac-1 and TER119.
Myeloid progenitors (CMPs, MEPs, and GMPs)
express Mac-1 at low levels and partially overlap
with the Gr-1/Mac-1 lineage–positive cells shown
in the bottom right panel. All panels: thin lines and
open symbols show wild-type data, and thick lines
and filled symbols show H2K-BCL-2 transgenic
data. All cultures were in Xvivo15 plus 30 ng/ml
rmKitl. Gray areas indicate background staining.
The left two panels of the top row show data from
a single sort, and the other panels show combined
data from four separate sorts. Cells were cultured in 96-well plates (500–1,000 cells/well) with daily medium change, and single wells were used for stain-
ing. The left two panels of the top row were cultured in Terasaki plates. 
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timing of their appearance. However, there are differences
in the absolute levels. H2K-
 
BCL
 
-2 transgenic cultures also
differ from wild-type cultures in the rate with which cells
with HSC phenotype, and CFU-S activity, disappear and
in the numbers of cells present in the cultures.
 
Multifactor Stimulation Will Increase the Proliferation Rate of
Wild-Type HSCs.
 
Stimulation with Kitl allows efficient
growth of H2K-
 
BCL
 
-2 transgenic but not wild-type
HSCs. Both grow fast when stimulated by multiple factors.
Several factors were tested for their ability to augment Kitl-
induced growth of wild-type HSCs to transgenic levels
(Fig. 6). LIF and Flt-3L do not affect the proliferation rate
of Kitl-stimulated cultures. However, although Tpo by it-
self does not induce rapid growth in wild-type HSCs, in
combination with Kitl it leads to vigorous growth, indistin-
guishable from that seen in transgenic cultures. A similar ef-
fect can be seen with IL-6 (results not shown).
 
BCL-2 Cannot Rescue a c-Kit Deficiency In Vivo.
 
To
study the interaction between the BCL-2 and c-Kit in
vivo, H2K-
 
BCL
 
-2 transgenic mice were crossed with mice
carrying the c-
 
Kit
 
W41 allele (28, 29). c-KitW41/W41 mice
have a white spotted appearance, are fertile, and have de-
creased numbers of peritoneal mast cells. The W41 pheno-
type, e.g., coat color, is similar in the presence of the H2K-
BCL-2 transgene. Multiparameter flow cytometric analysis
of blood, bone marrow, spleen, thymus, and peritoneal
cavity revealed only minor differences between W41 and
wild-type mice (such as decreased numbers of c-Kit bright
cells in the peritoneal cavity). These differences were not
rescued by the H2K-BCL-2 transgene (Table I), despite
the fact that the transgene is expressed, and functional, in
bone marrow–derived mast cells (BMMCs [20]). Cytospins
from W41 mice show a highly significant reduction of mast
cells in the peritoneal cavity of W41 mice compared with
wild-type mice (P 5 0.0001, t test; Fig. 7 and Table I).
Their numbers are not rescued by the H2K-BCL-2 trans-
gene. There are no significant differences between wild-
type and H2K-BCL-2 transgenic mice (P 5 0.1248) and
between c-KitW41/W41 and H2K-BCL-2/c-KitW41/W41 mice
with respect to mast cell numbers (P 5 0.9432). The mu-
tant c-Kit allele in W41 mice does not impair the effects of
BCL-2 overexpression. H2K-BCL-2/c-KitW41/W41 mice
have increased spleen and thymus sizes, comparable to
those caused by the transgene on a wild-type background.
Discussion
Exposure of cells to a growth factor can result in alter-
ations in proliferation, differentiation, or survival (30, 31).
It is difficult to distinguish between these effects in an envi-
ronment in which multiple stimuli are presented simulta-
neously, all the more so because stimulation with a factor
can have more than one outcome. To avoid this, HSCs
were studied under serum-free conditions as single plated
cells. However, growth factors that do not prevent apopto-
sis will not read out under these conditions. A wider range
of responses can be observed when cells are prevented from
undergoing growth factor deprivation–induced apoptosis.
One method for achieving this is ectopic expression of pro-
teins that block apoptosis, such as BCL-2. This was used to
test whether stimuli that induce a growth response can be
separated from those that prevent apoptosis in HSCs.
Overexpression of BCL-2 prevents a wide range of cells
from undergoing apoptosis induced by a wide range of
stimuli, including growth factor deprivation. Cell survival
is one of the essential functions of growth factors, although
Figure 6. A comparison of H2K-BCL-2 and wild-type: dual factor
stimulations. Single HSCs are clone sorted into Terasaki wells containing
Xvivo15 and growth factors as indicated. Gray lines show stimulation
with Kitl only, and black lines show cultures with factor combinations as
indicated. Cell numbers at each time point are plotted as total cell num-
bers present in all wells divided by the number of cells plated initially in
the experiment. A representative experiment is shown.
Table I. Relative Mast Cell Numbers in the Peritoneal Cavity
Wild-type H2K-BCL-2 W41/W41
H2K-BCL-2 1
W41/W41
Cytospins 1.9% 1.0% 0.3% 0.3%
(30/1,593) (11/1,057) (4/1,423) (4/1,353)
c-Kithigh 2.6% 1.1% 0.4% 0.3%
Cells with mast cell morphology present in cells washed from the
peritoneal cavity were quantitated in random fields of May-Grünwald/
Giemsa–stained cytospins as depicted in Fig. 7. c-Kit bright cells in the
peritoneal cavity were quantitated by flow cytometry on 2–5 3 104 cells
per mouse analyzed.1714 HSCs Need BCL-2 and Kitl to Prevent Apoptosis
it is certainly not the only function. The importance of cy-
tokine-mediated survival of cells in vivo has been demon-
strated most clearly in crosses between BCL-2 transgenic
mice, and IL (receptor) null mutant mice. Providing sur-
vival signals can actually be the only essential function on
subclasses of target cells (32–35). Some growth factors,
even though they may have potent activities, are not effi-
cient at preventing apoptosis. For example, Kitl is an im-
portant factor for many progenitors and stem cells but also
for BMMCs, which will proliferate readily when stimu-
lated by Kitl (36, 37). However, BMMC cultures stimulated
by Kitl only are much less stable than cultures stimulated by
IL-3, and undergo rapid apoptosis upon factor withdrawal
(38). One of the reasons for this difference may be the fact
that Kitl does not induce expression of Bcl-2 family mem-
bers in BMMCs (39). Kitl-induced protection against ap-
optosis seems to employ a separate biochemical pathway
(40). Kitl-induced expression of Bcl-2 has been reported
for NK cells (41).
Tpo, the ligand interacting with the c-Mpl receptor is a
major regulator of megakaryocytopoiesis and throm-
bopoiesis, but also has potent effects on HSCs (for reviews,
see references 42–44). We find that HSCs that overexpress
BCL-2 have a higher plating efficiency when plated in Tpo
as a single factor, indicating that Tpo stimulation alone is
not sufficient to block apoptosis. IL-3 induces proliferation
and rapid myeloid differentiation in a subset of plated
HSCs, in agreement with published observations (45, 46),
although this may depend on exact culture conditions (47).
The limited response to IL-3 may partially be a strain phe-
nomenon; C57BL mice are known to be poor IL-3 re-
sponders (38, 48).
Kitl/c-Kit signaling is important for dermal, gonadal,
and hematopoietic development (for reviews, see refer-
ences 49 and 50). Although there is debate about the exist-
ence of c-Kitneg HSCs (see, for example, reference 51), it is
clear that HSC activity is present in c-Kitpos cells in un-
treated bone marrow of both wild-type and H2K-BCL-2
transgenic mice (5, 13, 52, 53). c-Kit has been used as a se-
lection marker for HSCs and all the plated cells are c-Kitpos.
Although c-Kit null mutant mice have severe hematopoi-
etic deficiencies, their HSCs do expand during fetal devel-
opment, indicating that c-Kit is not essential for HSCs (54).
Kitl collaborates with many other growth factors in stimu-
lating cells; few cell types proliferate in response to Kitl
only. Kitl acts on hematopoietic progenitor cells, where it
is reported to increase survival, rather than recruitment into
the cell cycle (55–58), although it has also been reported to
shorten the dormant period of progenitor cells stimulated
by additional factors (59).
The action of Kitl on BCL-2–overexpressing HSCs is
remarkably different from that on wild-type cells. A few of
the latter will undergo a limited number of cell divisions
but the total number of cells remains below input numbers.
However, the majority of transgenic cells will cycle, many
of them extensively, and cell numbers exceed input num-
bers within days. Many of the cycling cells retain primitive
characteristics, although most eventually lose their HSC
phenotype, with respect to both surface markers and day 12
CFU-S activity. The initial increase in transgenic CFU-S
activity most likely reflects differentiation of LT-HSCs,
which are relatively inefficient at forming spleen colonies,
into ST-HSCs, which do this with higher efficiency (5). In
addition to progenitor cells, more mature myeloid cells are
Figure 7. The H2K-BCL-2
transgene does not rescue the W41
c-Kit allele.  May-Grünwald/Gi-
emsa–stained cytospins of cells
washed from the peritoneal cavity
of wild-type (left) and H2K-
BCL-2 transgenic mice (right).
Top panels show mice with both
wild-type c-Kit alleles, and the
bottom panels show mice ho-
mozygous for the W41 allele. The
split panel on the bottom right
shows cytospins from two differ-
ent mice. Arrowheads indicate
mast cells, which are abundantly
present in the top panels but al-
most absent in the bottom panels.1715 Domen and Weissman
present after 2 wk of culturing; almost all cells express my-
eloid surface markers such as Gr-1 and/or Mac-1. However,
some cells with the characteristics of HSCs remain present
for .1 wk. Culturing of HSCs in growth factor combina-
tions containing Kitl can abrogate the difference in prolif-
eration between wild-type and transgenic HSCs. In line
with other studies, we find that factors like Tpo and IL-6,
when combined with Kitl, can recruit wild-type cells into
rapid cycling (60, 61). Flt3-L does not collaborate with Kitl
in this respect, and neither does LIF.
Thus, provision of HSC survival via enforced expression
of BCL-2 and Kitl/c-Kit signaling is sufficient not only to
trigger HSC proliferation, but these proliferations result in
expansion of differentiating progenitors along the myeloid
line, without expansion of HSCs by self-renewal. Further-
more, the response of single HSCs is wildly asynchronous,
with some HSCs showing the first proliferative response
weeks after culture initiation. This differs from previously
published data (see, for example, reference 59), which
show an asynchronous response to IL-3, with addition of
Kitl reducing the dormancy times. Possible explanations for
this apparent discrepancy may be found in the different cell
populations that were used: FACS®-purified LT-HSCs
versus 5-fluorouracil–treated bone marrow. If we assume
that BCL-2 provides only a survival function for single
HSCs, and that the serum-free Xvivo15 medium contains
no ligands for other HSC receptors, signal transduction via
c-Kit on stem cells can open the cellular programs for my-
elopoiesis (30), or simply allow some self-autonomous pro-
cess to take advantage of the states of survival and prolifera-
tion to exact its program, in line with previous suggestions
(19, 31). It is unlikely that Kitl would enforce myeloid-
only differentiation in view of its importance in lymphoid
differentiation (25). The lack of large numbers of lymphoid
progeny from Kitl-stimulated HSCs does not reflect an in-
herent inability to undergo lymphoid differentiation: when
cells with CLP phenotype are sorted away from the rest of
the culture, they are capable of differentiating into B lym-
phoid cells. Rather, it may indicate an inhibitory activity
from the majority of cells undergoing myeloid differentia-
tion. Two determined oligopotent progenitors, the clonal
CLPs (26) and the clonal CMPs (27), have been character-
ized by us. CMPs give rise, without self-renewal, to GMPs
and MEPs. We show here that these progenitor classes
(CLPs, CMPs, MEPs, and GMPs) are all present in Kitl-
stimulated cultures initiated with LT-HSCs from H2K-
BCL-2 transgenic mice. It will be important to follow the
maturation pathways of H2K-BCL-2 HSCs in response to
Kitl, especially to determine whether single HSCs can give
rise to both CLPs and CMPs, and if so, whether this in-
volves asymmetric divisions.
It is conceivable that single H2K-BCL-2 HSCs respond
to Kitl by initiating production of hematopoietic cytokines
and/or their cognate receptors. For example, signal trans-
ducer and activator of transcription (Stat)-5, which has
been reported to be activated after Kitl/c-Kit signaling
(50), can induce expression of immediate early genes, in-
cluding IL-6 (62). It will be important to test whether
stimulated HSCs or their progeny produce cytokine tran-
scripts, to block the effects of secreted autocrine factors by
providing neutralizing antibodies or molecules in these cul-
tures, and/or use cytokine mutant mouse HSCs. Conceiv-
ably, Kitl could lead H2K-BCL-2 HSCs to undergo self-
renewing expansions of HSCs if the myelopoietic pathways
are so blocked.
If wild-type HSCs cannot respond to Kitl, but H2K-
BCL-2 HSCs can, it is reasonable to speculate that other
factors or signals are normally functioning in vivo to pro-
mote HSC survival under conditions of stimulation. Al-
though factors like Tpo, IL-6, and others readily do so in
Figure 8. Model for apoptosis signaling in HSCs. The middle two ar-
rows in each panel represent the two active apoptosis pathways that need
to be blocked. It is currently unclear whether these represent two com-
pletely separate pathways, or two actions within one pathway. White ar-
rows and text show the inactive pathway. Black arrows and text show the
active signaling pathway. Bcl-2 is meant to represent antiapoptosis Bcl-2
family members. The top panel shows Kitl signaling in the wild-type
HSCs. Although the proliferative signal from Kitl is conveyed, apoptosis
is blocked only partially at best. In the middle panel, transgene-derived
BCL-2, in combination with Kitl/c-Kit–transmitted signals, blocks apop-
tosis, allowing the Kitl-conveyed proliferation, and possibly differentia-
tion-inducing activities to be seen. In the bottom panel, multifactor stim-
ulation also completely blocks apoptosis and results in specific
proliferation/differentiation, depending on the factor combination used.1716 HSCs Need BCL-2 and Kitl to Prevent Apoptosis
vitro, they also promote HSC differentiation. We are in-
vestigating other factors/receptors for such signals, includ-
ing the Wnt/Frizzled  (63) and the Jagged/Notch (64)
ligand–receptor pairs.
Regulation of apoptosis in HSCs is very strict. Although
many cells can be induced to undergo apoptosis by signal-
ing through different pathways (65, 66), HSCs need input
from two signaling pathways to prevent apoptosis (Fig. 8).
Similar observations have been made in serum-free cultures
of certain other primary cells. Retinal pigmented epithelial
cells need both Bcl-XL and FGF1/extracellular signal–reg-
ulated kinase (Erk) signaling; Bcl-XL alone is not sufficient
to prevent apoptosis (67). This high level of control may
help to prevent transformation. The cytokine that seems to
be able to block both apoptosis pathways in HSCs, IL-3,
also conveys a strong myeloid differentiation signal. A sim-
ilar dual antiapoptosis signaling role has also been proposed
for IL-6 in T cells (68). In this system, IL-6 induces Bcl-2
expression in a Stat-3–independent manner, but preventing
apoptosis depends on the presence of functional Stat-3 pro-
tein. The Stat-3–dependent antiapoptotic signaling path
seems to involve Pim-1 and Cdc48p/valosine-containing
protein downstream of Stat-3 (69). In HSCs, we find that
IL-6 as a single factor is not sufficient, not even in H2K-
BCL-2 transgenic HSCs; combined stimulation with Kitl is
necessary for survival and proliferation. In our model (Fig.
8), this would indicate that only the Bcl-2–inducing part of
IL-6 antiapoptosis signaling is functional in murine HSCs.
It should be kept in mind that Fig. 8 necessarily only pre-
sents a subset of even the known interactions; apoptosis
prevention by Kitl, for example, is not independent of Bcl-2
(family members) in all cells. Kitl has been reported to up-
regulate Bcl-2 in NK cells (41) and Mcl-1 in myeloid cells
(70), and it can also functionally affect Bcl-2 by regulating
Bad phosphorylation by the protein–serine/threonine ki-
nase Akt (50, 71).
H2K-BCL-2 transgenic mice should prove very useful
in unravelling the growth factor requirements, and growth
factor activities, not only for HSCs but also for various
other multipotent and more lineage-restricted hematopoi-
etic progenitor populations that also express the transgene
(5, 26, 27), as well as cells in the nonhematopoietic lineages
that express the transgene. Cells from H2K-BCL-2 trans-
genic mice allow the distinction between factors acting on
survival and on proliferation/differentiation. They also fa-
cilitate factor characterization experiments through the in-
herently higher plating efficiencies. The culture conditions
described here, single cell plating of HSCs in serum-free
medium in the presence of Kitl, which allows the cells to
differentiate into lymphoid and the various myeloid lin-
eages, will be a powerful tool in these studies. We are cur-
rently using cells from these mice to look in more detail at
the actions of various factors involved in the decision be-
tween apoptosis, proliferation, and differentiation.
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